Welcome to TL;DR IBD (or Too Long, Didn't Read IBD), where I post succinct capsule summaries of the latest papers in IBD in 4 minutes, or less In the first episode, I summarize the EXIT trial, which sought to evaluate whether withdrawal of Anti-TNF therapy is a reasonable option

I’d like to thank the over 200 IBD, physicians and patients who have followed Too Long Didn’t Read: IBD in its first 48 hours Please feel free to comment with your ideas for improvements, comments about the studies, and suggestions for papers you would like to see reviewed in

New Video Dropping Tomorrow Follow along for my capsule summary of the QUASAR study assessing the IL-23 Inhibitor GUSELKUMAB for patients with moderate to severe UC

Hello TL;DR-IBD Followers! Here is my latest video breaking down the QUASAR Study evaluating the efficacy of the IL-23 Inhibitor Guselkumab (TREMFYA) in Ulcerative Colitis! Do IL-23s have a place in UC? Should we use them First Line? Are there differences between the IL-23s?